ALMKT:EPA
Mauna Kea Technologies SA
€0.088
arrow_downward
-1.79%(-0.0016) 1D
Nov 20, 1:54:26 PM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALMKT...
Open
€0.09
High
€0.09
Low
€0.09
Mkt. cap
16.92M
Avg. vol.
406.96K
Volume
206.88K
P/E ratio
0.75
52-wk high
€0.23
52-wk low
€0.07
EPS
€0.12
Shares outstanding
195.26M
No. of employees
56
Open
€0.09
High
€0.09
Low
€0.09
Mkt. cap
16.92M
Avg. vol.
406.96K
Volume
206.88K
P/E ratio
0.75
52-wk high
€0.23
52-wk low
€0.07
EPS
€0.12
Shares outstanding
195.26M
No. of employees
56
News stories
From web sources and news partners
marketscreener.com
·
51 minutes ago
Societe Generale sees S&P 500 ending 2027 at 8,500 on AI, earnings support
Traders Union
·
24 minutes ago
Mohamed A. El-Erian: S&P 500 may face longest losing streak since 2020 as 10-year Treasury yield falls
24/7 Wall St.
·
23 minutes ago
The S&P 500 Just Had Its Biggest Reversal Since March 2020
Profile
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts.
The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues.
Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time.
Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia
About Mauna Kea Technologies SA
CEOSacha Loiseau
Employees56
Founded2000
Headquarters-
SectorHealth Care
IndustryMedical device
Websitemaunakeatech.com